摘要
目的 分析多西他赛联合顺铂(DP)在中晚期非小细胞肺癌(NSCLC)中的应用价值。方法 选取我院2018年3月-2019年5月58例中晚期NSCLC患者,随机数字表法分为两组,对照组29例使用顺铂治疗,观察组29例采用DP治疗。比较两组临床疗效、治疗前后基质金属蛋白酶(MMP)水平、低剂量CT灌注参数、凋亡抑制基因Survivin及抑癌基因PTEN水平。结果 观察组临床治疗有效率86.21%高于对照组62.07%(P<0.05);观察组治疗后MMP-2、MMP-9水平低于对照组(P<0.05);观察组治疗后Survivin低于对照组,PTEN高于对照组(P<0.05);观察组治疗后血容量(BV)、强化峰值(PEI)、灌注值(perfusion)低于对照组(P<0.05)。结论 DP能提高中晚期NSCLC的疗效,改善患者MMP水平及低剂量CT灌注参数,调节凋亡抑制基因Survivin及抑癌基因PTEN的表达。
Objective To analyze the application value of docetaxel-cisplatin(DP) in advanced non-small cell lung cancer(NSCLC). Methods A total of 58 patients with advanced NSCLC in the hospital were enrolled between March 2018 and May 2019. They were randomly divided into two groups. The control group(29 cases) were treated with cisplatin, while observation group(29 cases) were treated with DP. The clinical curative effect, level of matrix metalloproteinase(MMP), low-dose CT perfusion parameters, levels of apoptosis inhibitory gene Survivin and tumor suppressor gene PTEN before and after treatment were compared between the two groups. Results The effective rate of the observation group was 86.21% higher than that of the control group 62.07%(P<0.05). The levels of MMP-2, MMP-9, Survivin, blood volume(BV), peak enhancement image(PEI) and perfusion value(perfusion) in the observation group were lower than those in the control group, while PTEN was higher than those in the control group(P<0.05). Conclusion DP can improve clinical curative effect on advanced NSCLC, improve MMP level and low-dose CT perfusion parameters, and regulate the expressions of Survivin and PTEN.
作者
钟家将
张东伟
蓝冰
宁宇
杨朝生
邹博
ZHONG Jia-jiang;ZHANG Dong-wei;LAN Bing;NING Yu;YANG Chao-sheng;ZOU Bo(Department of Respiratory and Critical Care Medicine,Liuzhou People's Hospital,Liuzhou 545000,Guangxi,China;Department of Radiology,Liuzhou People's Hospital,Liuzhou 545000,Guangxi,China)
出处
《中国CT和MRI杂志》
2023年第1期72-73,179,共3页
Chinese Journal of CT and MRI
关键词
多西他赛
顺铂
非小细胞肺癌
低剂量CT灌注成像
Docetaxel
Cisplatin
Non-Small Cell Lung Cancer
Low-Dose CT Perfusion Imaging
